PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts, July 28, 2009: ACOR, VIRL, OSIR, BCRX, TPTX and AVII.

-- July 27, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR | Quote | Chart | News | PowerRating) closed at $26.35 on a volume of 323,472 shares.

In a press release out on July 28, 2009 Acorda Therapeutics to Host Conference Call to Report Second Quarter 2009 Financial Results on August 4, 2009

HAWTHORNE, N.Y., Jul 28, 2009 -- Acorda Therapeutics, Inc. (Nasdaq: ACOR | Quote | Chart | News | PowerRating) announced today that it will report its financial results for the second quarter 2009 on Tuesday, August 4, 2009 at 8:30 a.m. ET before the U.S. financial markets open.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

-- July 27, 2009 Virage Logic Corporation (NASDAQ:VIRL) closed at $5.18 on a volume of 15,907 shares

In a press release on july 28, 2009 Virage Logic Introduces Volume Production-Proven SiPro(TM) PCI Express PHY IP

SAN FRANCISCO, Jul 28, 2009 -- Virage Logic Corporation (NASDAQ:VIRL), the semiconductor industry's trusted IP partner, today announced its new offering, a silicon and volume production-proven 40-nanometer (nm) G PCI Express Gen1/Gen2 Physical Layer (PHY). The SiPro(TM) PCI Express PHY product line represents the first offering in Virage Logic's advanced interface IP SiPro product portfolio that is a result of its collaboration with AMD announced in January 2009. This agreement grants Virage Logic the rights to license and modify certain AMD standards-based advanced interface IP that was designed for and used in the 40nm ATI Radeon(TM) graphics products from AMD.

About Virage Logic

Virage Logic is a leading provider of semiconductor intellectual property (IP) for the design of complex integrated circuits. The company's highly differentiated product portfolio includes embedded SRAMs, embedded NVMs, embedded memory test and repair, logic libraries, memory development software, and interface IP solutions. As the industry's trusted semiconductor IP partner, foundries, IDMs and fabless customers rely on Virage Logic to achieve higher performance, lower power, higher density and optimal yield, as well as shorten time-to-market and time-to-volume. For further information, visit http://www.viragelogic.com.

-- July 27, 2009 Osiris Therapeutics, Inc. (NASDAQ:OSIR) closed at $12.83 on a volume of 149,356 shares.

In a press release out on July 28, 2009 Osiris Achieves Milestone Payment for Progress Developing Stem Cell Therapy for Type 1 Diabetes

Review of Safety Data Leads to Expansion of Clinical Trial to Include Pediatric Patients

COLUMBIA, Md., Jul 28, 2009 -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for progress made on a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The payment was triggered after one-half of the patients in the 60-participant study were enrolled, a milestone in the funding agreement with the JDRF. The trial is also being expanded to include pediatric patients, opening enrollment to patients between 12 and 35 years of age. Osiris and the JDRF entered into a partnership in 2007 for the development of Prochymal as a therapy for newly diagnosed type 1 diabetes mellitus.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, orthopedic and cardiovascular areas. The Company's pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune, and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company, with capabilities in research, development, manufacturing, and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology including 49 U.S. patents each having one or more foreign counterparts. Osiris, Prochymal and Chondrogen are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)

-- July 27, 2009 BioCryst Pharmaceuticals (Nasdaq: BCRX | Quote | Chart | News | PowerRating) closed at $10.95 on a volume of 5,225,649 shares.

In a press release out on July 28, 2009 BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009

BIRMINGHAM, Ala., July 28, 2009 -- BioCryst Pharmaceuticals (Nasdaq: BCRX | Quote | Chart | News | PowerRating) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in oncology, infectious and autoimmune diseases. BioCryst has two product candidates in pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to expand its portfolio of next-generation therapeutic candidates with the potential to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings, Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

-- July 27, 2009 TorreyPines Therapeutics, Inc. (Nasdaq: TPTX | Quote | Chart | News | PowerRating) closed at $0.09 on a volume of 68,137 shares.

In a press release out on July 28, 2009 Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

NOVATO, Calif. and LA JOLLA, Calif., July 28, 2009 -- Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX), today announced that they have entered into a definitive merger agreement. Upon closing, the merger will result in a Nasdaq-listed biopharmaceutical company with a pipeline of mid- to late-stage clinical development candidates and preclinical drug targeting platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations. It is anticipated that the merged company will be named Raptor Pharmaceuticals Corp. and be headquartered in Novato, California.

About TorreyPines

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com.

-- July 27, 2009 AVI BioPharma, Inc. (NASDAQ: AVII | Quote | Chart | News | PowerRating) closed at $2.10 on a volume of 2,511,707 shares

In a press release out on July 28, 2009 AVI BioPharma and Action Duchenne Team Up to Support Advancement of PMO-Based Therapeutics for Treatment of Duchenne Muscular Dystrophy

Action Duchenne Provides $1.2m to Support Continuing Development of Drugs to Treat Duchenne Muscular Dystrophy

CORVALLIS, OR and LONDON, Jul 28, 2009 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, and Action Duchenne, a leading UK charity dedicated to increasing awareness, engendering action and raising funds to find a cure for Duchenne Muscular Dystrophy (DMD), today announced a collaboration to support the acceleration of research and development for AVI's exon skipping candidate drugs for the treatment of DMD.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

About PicksThatMove.com

www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.

www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com

www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

CONTACT: PicksThatMove.com
e-mail: Info@picksthatmove.com
WWW: http://www.picksthatmove.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Virage Logic Corporation (VIRL) VIRL. Virage Logic Corporation (VIRL) has Short Term PowerRatings at TradingMarkets. Details on Virage Logic Corporation (VIRL) Short Term PowerRatings is available at This Link.

For full details on Osiris Therapeutics Inc (OSIR) OSIR. Osiris Therapeutics Inc (OSIR) has Short Term PowerRatings at TradingMarkets. Details on Osiris Therapeutics Inc (OSIR) Short Term PowerRatings is available at This Link.

For full details on Acorda Therapeutics Inc (ACOR) ACOR. Acorda Therapeutics Inc (ACOR) has Short Term PowerRatings at TradingMarkets. Details on Acorda Therapeutics Inc (ACOR) Short Term PowerRatings is available at This Link.

For full details on Biocryst Pharmaceuticals (BCRX) BCRX. Biocryst Pharmaceuticals (BCRX) has Short Term PowerRatings at TradingMarkets. Details on Biocryst Pharmaceuticals (BCRX) Short Term PowerRatings is available at This Link.

For full details on Avi Biopharma Inc (AVII) AVII. Avi Biopharma Inc (AVII) has Short Term PowerRatings at TradingMarkets. Details on Avi Biopharma Inc (AVII) Short Term PowerRatings is available at This Link.

For full details on Torreypines Therapeutics Inc (TPTX) TPTX. Torreypines Therapeutics Inc (TPTX) has Short Term PowerRatings at TradingMarkets. Details on Torreypines Therapeutics Inc (TPTX) Short Term PowerRatings is available at This Link.